CTSO
Cytosorbents Corp
NASDAQ · Healthcare · Medical - Devices · US
$4.96
+20.68%Year over year
Reported trailing growth
- Revenue
- +3.1%
- EBITDA
- -91.0%
- EBIT
- +22.1%
- EPS
- —
- Free cash flow
- -1.4%
- Operating cash flow
- -5.4%
Forward estimates
Based on analyst estimates
- Revenue
- +20.5%
- EBITDA
- +110.1%
- EPS
- +91.7%
Three-year CAGR
- Revenue
- +2.2%
- EBITDA
- +77.4%
- EBIT
- +13.5%
- Net income
- +60.4%
- EPS
- +65.8%
- Free cash flow
- +14.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026